Genomma Lab Internacional S.A.B. de C.V - Asset Resilience Ratio
Genomma Lab Internacional S.A.B. de C.V (LABB) has an Asset Resilience Ratio of 0.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LABB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Genomma Lab Internacional S.A.B. de C.V's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Genomma Lab Internacional S.A.B. de C.V.
Liquid Assets Composition Over Time
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Genomma Lab Internacional S.A.B. de C.V's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$213.62 Million | 0.9% |
| Total Liquid Assets | MX$213.62 Million | 0.90% |
Asset Resilience Insights
- Limited Liquidity: Genomma Lab Internacional S.A.B. de C.V maintains only 0.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genomma Lab Internacional S.A.B. de C.V Industry Peers by Asset Resilience Ratio
Compare Genomma Lab Internacional S.A.B. de C.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082 |
Drug Manufacturers - Specialty & Generic | 0.24% |
Annual Asset Resilience Ratio for Genomma Lab Internacional S.A.B. de C.V (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Genomma Lab Internacional S.A.B. de C.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.90% | MX$213.62 Million ≈ $12.29 Million |
MX$23.83 Billion ≈ $1.37 Billion |
+0.53pp |
| 2024-12-31 | 0.37% | MX$89.25 Million ≈ $5.14 Million |
MX$24.08 Billion ≈ $1.39 Billion |
-0.51pp |
| 2023-12-31 | 0.89% | MX$183.23 Million ≈ $10.55 Million |
MX$20.70 Billion ≈ $1.19 Billion |
-0.07pp |
| 2022-12-31 | 0.95% | MX$205.93 Million ≈ $11.85 Million |
MX$21.61 Billion ≈ $1.24 Billion |
+0.81pp |
| 2017-12-31 | 0.15% | MX$23.21 Million ≈ $1.34 Million |
MX$15.89 Billion ≈ $914.23 Million |
-0.15pp |
| 2015-12-31 | 0.30% | MX$52.07 Million ≈ $3.00 Million |
MX$17.63 Billion ≈ $1.01 Billion |
+0.23pp |
| 2014-12-31 | 0.07% | MX$17.84 Million ≈ $1.03 Million |
MX$25.43 Billion ≈ $1.46 Billion |
+0.02pp |
| 2013-12-31 | 0.05% | MX$8.13 Million ≈ $467.65K |
MX$17.35 Billion ≈ $998.66 Million |
-0.21pp |
| 2012-12-31 | 0.25% | MX$32.75 Million ≈ $1.88 Million |
MX$12.99 Billion ≈ $747.73 Million |
-6.55pp |
| 2007-12-31 | 6.81% | MX$81.26 Million ≈ $4.68 Million |
MX$1.19 Billion ≈ $68.72 Million |
-- |
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more